Indomethacin Capsule, Extended Release
FDA Recall NDC 68462-325

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 2 recorded enforcement report(s) associated with Indomethacin (NDC 68462-325). A significant event, classified as Class II, was initiated on Mar 13, 2025 by Glenmark Pharmaceuticals Inc., Usa. The reported reason for this action was: "CGMP Deviations"

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

March 2025 Class II Recall: CGMP Deviations

Recall Number
Class II Ongoing
Reason for Recall
CGMP Deviations
Initiated
Mar 13, 2025
Reported
Apr 16, 2025
Quantity
N/A

Recall Profile & Regulatory Data

Event ID
96474
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Glenmark Pharmaceuticals Inc., USA
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
U.S. Nationwide
Product Description
Indomethacin Extended-Release Capsules, 75mg, 60-count bottles, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc. USA, Mahwah, NJ 07430. NDC# 68462-325-60
Batch or Lot Expiration Information
Lot# 17232323, exp. date Oct-25 17232335, exp. date Oct-25 17232323, exp. date Oct-25
Affected Packages Involved in this Recall
68462-325-60Product
68462-325-90Product
68462-325-01Product
68462-325-05Product
68462-325-10Product

July 2024 Class II Recall: Failed Dissolution Specifications

Recall Number
Class II Ongoing
Reason for Recall
Failed Dissolution Specifications: below specification results
Initiated
Jul 31, 2024
Reported
Sep 04, 2024
Quantity
2404 bottles

Recall Profile & Regulatory Data

Event ID
95075
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Glenmark Pharmaceuticals Inc., USA
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide USA
Product Description
Indomethacin Extended-Release Capsules, USP, 75 mg, packaged in a) 60-count bottle (NDC 68462-325-60) and b) 90-count bottle (NDC 68462-325-90), Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Plot No. 2 Phase-2, Pharma Zone, SEZ, Pithampur, Dist-Dhar, Madya Pradesh - 454775, India Mfg Llc. No: 25/9/2010, Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430.
Batch or Lot Expiration Information
Lot# : 17240105, Exp 12/31/2025
Affected Packages Involved in this Recall
68462-325-60Product
68462-325-90Product
68462-325-01Product
68462-325-05Product
68462-325-10Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.